Phoenix Biotech Acquisition's Comment on Sales, Marketing and Customers
The company develops engineered T cell therapeutics for cancer treatment. Its lead product, CER-1236, targets the TIM-4 ligand tumor antigen and is intended for hematological malignancies and solid tumors. A Phase 1 clinical trial for CER-1236 has been initiated in patients with acute myeloid leukemia (AML), including relapsed/refractory AML, AML in remission with measurable residual disease, and newly diagnosed patients with TP53 mutated myelodysplastic syndrome/AML. The company has also submitted an investigational new drug (IND) application for CER-T cell therapy in non-small cell lung cancer (NSCLC) and ovarian cancer, with a Phase 1 study expected to begin in early 2026. The ongoing Phase 1/1b study is multi-center and open-label, assessing safety, therapeutic utility, and dosing. To date, cell products have been manufactured and administered to four patients.
Phoenix Biotech Acquisition’s Comment on Sales, Marketing and Customers
The company develops engineered T cell therapeutics for cancer treatment. Its lead product, CER-1236, targets the TIM-4 ligand tumor antigen and is intended for hematological malignancies and solid tumors. A Phase 1 clinical trial for CER-1236 has been initiated in patients with acute myeloid leukemia (AML), including relapsed/refractory AML, AML in remission with measurable residual disease, and newly diagnosed patients with TP53 mutated myelodysplastic syndrome/AML. The company has also submitted an investigational new drug (IND) application for CER-T cell therapy in non-small cell lung cancer (NSCLC) and ovarian cancer, with a Phase 1 study expected to begin in early 2026. The ongoing Phase 1/1b study is multi-center and open-label, assessing safety, therapeutic utility, and dosing. To date, cell products have been manufactured and administered to four patients.
Sources:
Phoenix Biotech Acquisition Corp’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Phoenix Biotech Acquisition Corp’s corporate clients.
For your research, we’ve provided 9 tables on Phoenix Biotech Acquisition Corp corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
